Wildsmith S, Li W, Wu S, Stewart R, et al. Tumor Mutational Burden as a Predictor of Survival With Durvalumab and/or Tremelimumab Treatment in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma. Clin Cancer Res 2023 Feb 20:CCR-22-2765. doi: 10.1158/1078-0432.CCR-22-2765.
PMID: 36806911